Lysosomal-associated protein transmembrane 5 ameliorates non-alcoholic steatohepatitis by promoting the degradation of CDC42 in mice

[1]  W. Diao,et al.  Lysosomal protein transmembrane 5 promotes lung-specific metastasis by regulating BMPR1A lysosomal degradation , 2022, Nature Communications.

[2]  R. Malekzadeh,et al.  The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? , 2021, Journal of hepatology.

[3]  Lu Gao,et al.  Lysosomal-Associated Protein Transmembrane 5 Functions as a Novel Negative Regulator of Pathological Cardiac Hypertrophy , 2021, Frontiers in Cardiovascular Medicine.

[4]  A. Suzuki,et al.  Hepatic Mitochondrial SAB Deletion or Knockdown Alleviates Diet‐Induced Metabolic Syndrome, Steatohepatitis, and Hepatic Fibrosis , 2021, Hepatology.

[5]  Haibo Ding,et al.  Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages , 2021, Nature Communications.

[6]  K. Dou,et al.  Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1. , 2021, Cell metabolism.

[7]  Yuquan Wei,et al.  Role of lysosomes in physiological activities, diseases, and therapy , 2021, Journal of Hematology & Oncology.

[8]  C. Eapen,et al.  What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease? , 2020, Journal of clinical and experimental hepatology.

[9]  Feng-Sheng Wang,et al.  miR-29a Modulates GSK3β/SIRT1-Linked Mitochondrial Proteostatic Stress to Ameliorate Mouse Non-Alcoholic Steatohepatitis , 2020, International journal of molecular sciences.

[10]  M. Hwang,et al.  Lumenal Galectin-9-Lamp2 interaction regulates lysosome and autophagy to prevent pathogenesis in the intestine and pancreas , 2020, Nature Communications.

[11]  P. Trivedi,et al.  Lysosomal Biology and Function: Modern View of Cellular Debris Bin , 2020, Cells.

[12]  Yusu Gu,et al.  Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease , 2020, Science Translational Medicine.

[13]  Hongliang Li,et al.  Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease , 2019, Trends in Endocrinology & Metabolism.

[14]  S. Muller,et al.  Lysosomes as a therapeutic target , 2019, Nature Reviews Drug Discovery.

[15]  H. Zhang,et al.  Dual‐Specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through Transforming Growth Factor Beta–Activated Kinase 1 Suppression , 2019, Hepatology.

[16]  M. Febbraio,et al.  Preclinical Models for Studying NASH-Driven HCC: How Useful Are They? , 2019, Cell metabolism.

[17]  P. Ye,et al.  Dual‐Specificity Phosphatase 9 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through ASK1 Suppression , 2018, Hepatology.

[18]  Hongliang Li,et al.  Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases , 2018, Advanced science.

[19]  Hongliang Li,et al.  Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4 , 2017, Nature Medicine.

[20]  Roberto Zoncu,et al.  The Lysosome as a Regulatory Hub. , 2016, Annual review of cell and developmental biology.

[21]  A. Gentilini,et al.  Molecular Pathogenesis of NASH , 2016, International journal of molecular sciences.

[22]  T. Tsubata,et al.  LAPTM5 promotes lysosomal degradation of intracellular CD3ζ but not of cell surface CD3ζ , 2014, Immunology and cell biology.

[23]  T. Kurosaki,et al.  A Role for Lysosomal-Associated Protein Transmembrane 5 in the Negative Regulation of Surface B Cell Receptor Levels and B Cell Activation , 2010, The Journal of Immunology.

[24]  K. Das,et al.  Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease , 2010, Hepatology.

[25]  J. Taylor,et al.  Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. , 2008, Biochimica et biophysica acta.

[26]  M. Hatano,et al.  A lysosomal protein negatively regulates surface T cell antigen receptor expression by promoting CD3zeta-chain degradation. , 2008, Immunity.

[27]  D. Rotin,et al.  Transport of LAPTM5 to lysosomes requires association with the ubiquitin ligase Nedd4, but not LAPTM5 ubiquitination , 2006, The Journal of cell biology.

[28]  M. Pagliassotti,et al.  Hepatospecific effects of fructose on c-jun NH2-terminal kinase: implications for hepatic insulin resistance. , 2004, American journal of physiology. Endocrinology and metabolism.

[29]  Tzu-Ling Cheng,et al.  Regulation of anoikis by Cdc42 and Rac1. , 2004, Experimental cell research.

[30]  J. Rowley,et al.  LAPTM5: a novel lysosomal-associated multispanning membrane protein preferentially expressed in hematopoietic cells. , 1996, Genomics.

[31]  Yi Luo,et al.  Downregulation of LAPTM5 suppresses cell proliferation and viability inducing cell cycle arrest at G0/G1 phase of bladder cancer cells. , 2017, International journal of oncology.

[32]  F. Urano,et al.  Cdc42 and Rac1 are major contributors to the saturated fatty acid-stimulated JNK pathway in hepatocytes. , 2012, Journal of hepatology.